Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 31, 2019

Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments

GlobeNewswire May 8, 2019

Sarepta Announces Agreement with Nationwide Children's Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy

GlobeNewswire May 8, 2019

Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019

GlobeNewswire May 1, 2019

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 30, 2019

Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference

GlobeNewswire April 8, 2019

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 29, 2019

Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study

GlobeNewswire March 28, 2019

Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program

GlobeNewswire March 25, 2019

Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock

GlobeNewswire March 5, 2019

Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock

GlobeNewswire March 5, 2019

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 28, 2019

Sarepta Therapeutics Announces Second Year of Route 79, The Duchenne Scholarship Program

GlobeNewswire February 28, 2019

Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments

GlobeNewswire February 27, 2019

Sarepta To Pay $165M To Buy Out Myonexus, Reports Positive Results For Muscular Dystrophy Trial Results

Benzinga.com  February 27, 2019

Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

GlobeNewswire February 27, 2019

Sarepta Exercises Option to Acquire Myonexus Therapeutics

GlobeNewswire February 27, 2019

Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Benzinga.com  February 25, 2019

Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019

GlobeNewswire February 20, 2019

Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)

Business Wire February 14, 2019